Heterogeneity of duct carcinoma in situ (DCIS): Relationship of grade and subtype analysis to local recurrence and risk of invasive transformation
References (27)
- et al.
Non-invasive ductal carcinoma of the breast. The relevance of histologic categorization
Hum. Pathol.
(1993) - et al.
Extent, distribution, and mammographic/histologic correlations of breast ductal carcinoma in situ
Lancet
(1990) Duct carcinoma in situ: Pathology and treatment
Surg. Clin. Nth. Am.
(1990)- et al.
Follow-up of two treatment modalities for ductal cancer in situ of the breast
Br. J. Surg.
(1989) Problems in Breast Pathology
- et al.
Importance of cellular DNA content in premalignant breast disease and pre-invasive carcinoma of the female breast
Br. J. Surg.
(1987) - et al.
Image cytophotometric DNA analysis of atypical hyperplasias and intraductal carcinomas of the breast
Arch. Pathol. Lab. Med.
(1990) - et al.
Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer
N. Engl. J. Med.
(1993) - et al.
Histologic multiplicality of TIS, T1–2 breast carcinomas. Implications for clinical trials of breast conserving surgery
Cancer
(1985) - et al.
DNA analysis of ductal carcinoma of the breast: A comparison with histologic features
Cancer
(1991)
Duct carcinoma in situ: Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymphnode metastases, and short-term treatment failures
Cancer
Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence
Cancer
Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions
Cancer
Cited by (62)
Derivation of a nuclear heterogeneity image index to grade DCIS
2020, Computational and Structural Biotechnology JournalAccuracy of Breast Magnetic Resonance Imaging Compared to Mammography in the Preoperative Detection and Measurement of Pure Ductal Carcinoma In Situ: A Retrospective Analysis
2019, Academic RadiologyCitation Excerpt :Pure DCIS accounts for about 20% of malignant screen-detected breast lesions (3,4). Fifty percent of DCIS are high grade and comprise the risk of harbouring or progressing to high grade invasive cancer (5,6). About 30–50% of DCIS progress into invasive cancer and half of the tumor recurrences are invasive cancers (7,8).
Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: Critical review
2017, BreastCitation Excerpt :However, this may not fully represent the heterogeneity of DCIS. About 16% of low nuclear grade DCIS is mixed with either intermediate or high grade foci [54–56]. Reviewing 1059 cases of pure DCIS lesions diagnosed between 1990 and 2013 in Nottingham revealed that 13% of cases were pure low nuclear grade while 5.5% and 1.5% of low grade lesion were mixed with intermediate or intermediate and high grades respectively (unpublished data).
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study
2015, European Journal of CancerCitation Excerpt :Progression from DCIS to iBC constitutes a complex biological phenomenon [16,25]. It has been hypothesised that breast cancer evolution can be classified into two groups: a low- and high-grade breast neoplasia family [16,26–30]. The low- and high-grade multistep model of breast cancer progression based on morphological, immunophenotypical and molecular features described by Lopez-Garcia et al. suggests that if low-grade DCIS progresses to invasive disease this will be low-grade iBC with favourable characteristics in most cases and survival rates after treatment of this invasive cancer will still be excellent.
- 1
Clinical Associate Professor of Pathology, Stanford University, Stanford, California.